Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HCP1306 vs Co-administration of Rosuvastatin and Ezetimibe in Healthy Adults
NCT02941848Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Nov 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of ezetimibe + rosuvastatin in hypercholesterolemia (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 96 hours and Maximum Plasma Concentration at 96 hours. Started Nov 2014; status: completed.
02
Drugs
ezetimibe + rosuvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02941848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02941848.